DNA vector-based Stat3-specific RNA interference (si-Stat3) blocks Stat3 signalling and inhibits prostate tumour growth. However, the antitumour activity depends on the efficient delivery of si-Stat3. The effects on the growth of mouse prostate cancer cells of si-Stat3 delivered by hydroxyapatite were determined in this study. RM-1 tumour blocks were transplanted into C57BL/6 mice. CaCl 2 -modified hydroxyapatite carrying si-Stat3 plasmids were injected into tumours, and tumour growth and histology were determined. The expression levels of Stat3, pTyr-Stat3, Bcl-2, Bax, Caspase3, VEGF and cyclin D1 were measured by western blot analysis. Amounts of apoptosis in cancer cells were analysed with immunohistochemistry and the terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end-labelling (TUNEL) assay. The results showed that hydroxyapatite-delivered si-Stat3 significantly suppressed tumour growth up to 74% (P,0.01). Stat3 expression was dramatically downregulated in the tumours. The immunohistochemistry and TUNEL results showed that si-Stat3-induced apoptosis (up to 42%, P,0.01). The Stat3 downstream genes Bcl-2, VEGF and cyclin D1 were also strongly downregulated in the tumour tissues that also displayed significant increases in Bax expression and Caspase3 activity. These results suggest that hydroxyapatite can be used for the in vivo delivery of plasmid-based siRNAs into tumours.
INTRODUCTION
RNA interference (RNAi) is a method of post-transcriptional gene silencing. Small interfering RNAs (siRNAs) can be chemically synthesised or expressed from a DNA vector.
1,2 Recently, RNAi has been recognized as a novel and promising antitumour strategy. 3 However, one of the challenges of the in vivo application of siRNAbased therapies is the efficient delivery of siRNA, especially across the plasma membrane, to the cytoplasm of target cells.
Nanomedicine is a newly emerging practice that fuses nanotechnology and medicine. Nanoparticles have been used as diagnostic probes in targeted therapy. Hydroxyapatite (HAP) is the principal inorganic constituent of human bones and teeth, and its molecular formula is Ca 10 (PO 4 ) 6 (OH) 2 . 4 Synthetic HAP crystals are now widely used in medical implants and as coatings on prostheses. 5 Compared to viral vectors, which possess risks of pathogenicity and immunogenicity, synthetic HAP nanoparticles have favourable biocompatibility and high osteoconductivity and/or osteoinductivity without immunogenicity or proinflammatory features. [6] [7] [8] [9] HAP can not only directly inhibit the proliferation of cancer cells, 10 but also be used in a gene delivery system due to its safety, economy and efficiency. 11 Our previous study showed that Stat3-specific siRNA can markedly suppress Stat3 expression and inhibit the growth of prostate cancer cells. 12 In this study, HAP nanoparticles were used to mediate DNA vector-based Stat3-specific RNAi to treat prostate cancer in vivo, with the goal of investigating the in vivo antitumour efficacy of HAP nanoparticle-mediated RNAi.
MATERIALS AND METHODS
HAP and Stat3-specific siRNA plasmids HAP nanoparticles were purchased from Nanjing Emperor Nano Material Co. Ltd (Nanjing, China). Expression plasmids containing Stat3-specific siRNA were constructed in our laboratory. According to our previous study, the si-Stat3 most effective at inhibiting cancer growth is located at the SH2 domain of the mouse and human Stat3 genes. 12 Thus, this si-Stat3 (sequence: GCAGCAGCTGAACAACA-TG, spanning nucleotides 2144 to 2162; GenBank accession number: NM_003150) was used in the present study. A negative control si-scramble sequence (Ambion, Austin, TX, USA) without obvious homology to mouse or human gene sequences was used to eliminate nonspecific effects. HAP was ultrasonically processed for 10 min, and the final concentration was adjusted to 20 mg ml 21 . A CaCl 2 solution was prepared with double-distilled water at a final concentration of 0.25 mol l 21 . Then, 20 ml of HAP and 25 ml of CaCl 2 were gently mixed by repeated inversion and ultrasonically processed for 10 min. Subsequently, 20 mg (40 ml, 0.5 mg ml 21 ) of plasmid was added to the above solution, producing a final volume of 100 ml. This solution was incubated for 20 min at room temperature and mixed by repeated inversion before injection.
Cell culture and establishment of a mouse prostate cancer model The mouse prostate cancer cell line RM-1 was obtained from the Shanghai Institute of Cellular Research (Shanghai, China). These cells were grown in Iscove's modified Dulbecco's medium (GIBCO, Carlsbad, CA, USA) containing 10% foetal bovine serum (GIBCO). Then, RM-1 cells (2310 6 cells per 150 ml) were transplanted into mice subcutaneously to generate a primary cancer. Male C57BL/6 mice, weighing 18-22 g, were purchased from the Beijing Institute for Experimental Animals (Beijing, China). All animals were housed and experiments were performed according to the guidelines established by Jilin University for the ethical use of animals in research. The tumours were obtained, cut into 1.5-mm 3 blocks and implanted into the right flanks of C57BL/6 mice. Five days after implantation, the mice were divided into three groups (n58 per group) and independently injected intravenously with 100 ml of (i) phosphate-buffered saline (PBS) alone (mock), (ii) CaCl 2 -modified HAP carrying pSilencer neo 3.1-H1-Scrambled siRNA (HAP-si-Scramble; control), or (iii) CaCl 2 -modified HAP carrying pSilencer neo 3.1-H1-Stat3-siRNA (HAP-si-Stat3). CaCl 2 -modified HAP carrying plasmids (20 mg per mouse) were subcutaneously injected into the tumours at different sites using a syringe with a 27-gauge needle. The tumour volume was calculated approximately every 2 to 3 days according to the following formula: m 1 3m 2 30.5236 (m 1 : short diameter; m 2 : long diameter). 13 This process was repeated on day 20. The mice were killed on day 32, and the tumours from the different groups were obtained for immunohistochemistry and terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end-labelling (TUNEL) assays.
Semiquantitative reverse transcription-PCR (RT-PCR)
The mRNA expression levels of Stat3 and the Stat3 downstream genes were determined using semiquantitative RT-PCR. Total RNA was isolated from tumours using TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Reverse transcription was performed with 3 mg of total RNA in a final volume of 20 ml containing 10 mmol l 21 dNTP, 0.5 mg ml 21 oligo dT, 20 U RNasin and 200 U M-MLV reverse transcriptase (Promega Corp., Madison, WI, USA). PCR was performed in a final volume of 25 ml containing 25 mmol l 21 MgCl 2 , 2.5 mmol l 21 dNTP and 1 U Taq DNA polymerase (Invitrogen). The sequence of the PCR primers (Sangong Co. Ltd, Shanghai, China) was based on the mouse mRNA. The PCR products were separated by 1% agarose gel electrophoresis and visualised under UV light after 0.5% ethidium bromide staining. The primers specific to the candidate genes were designed using Primer 5 software (PREMIER Biosoft International, Palo Alto, CA, USA). The primer sequences were as follows: GAPDH sense, 59-GGGTGATGCTGGTGCTGAGTATGT-39 and antisense, 59-AAGAATGGGAGTTGCTGTTGAAGTC-39; Stat3 sense, 59-TTGCCAGTTGTGGTGATC-39 and antisense, 59AGAACCCAGA-AGGAGAAGC-39.
Western blot assay
Cell lysis, protein quantifications and Western blot assays were performed as previously described.
14 The anti-Stat3, anti-phospho-Tyr705-Stat3, anti-cyclin D1, anti-VEGF and anti-b-actin antibodies were obtained from Santa Cruz Biotech, Inc. (Santa Cruz, CA, USA). The anti-Bcl-2, anti-Bax and anti-cleaved-caspase3 antibodies were obtained from Cell Signalling Technology (Beverly, MA, USA). The protein bands were visualised by SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA), and the membranes were subjected to Xray autoradiography. Band intensities were determined with Quantity One software (Bio-Rad). Experiments were performed in triplicate, and the results were expressed as means6s.e.
Immunohistochemistry and TUNEL assay
Serial sections of tumour tissue excised from animals were fixed in formalin. Immunostaining was performed using the Vectastain Elite ABC avidin/biotin staining kit (Vector Laboratories Inc., Burlingame, CA, USA). Antibodies specific to Stat3, proliferating cell nuclear antigen (PCNA) and CD34 were obtained from Santa Cruz Biotech, Inc. The DeadEnd Fluorometric TUNEL System (Promega) was used to measure the fragmented DNA in apoptotic cells by catalytically incorporating fluorescein-12-dUTP at the 39-OH DNA ends using terminal deoxynucleotidyl transferase, recombinant (rTdT) (Promega). Paraffin-embedded tissues were cut into 3-mm sections, deparaffinised and hydrated according to standard protocols. 15 After incubation with proteinase K (20 mg ml 21 ) for 30 min at room temperature, the TUNEL reaction mix containing rTdT and the rTdT reaction mix was added to the slides, followed by incubation in a humidified chamber for 60 s at 37 uC. After being washed, the sections were immersed in 40 ml of freshly prepared propidium iodide solution (1 mg ml 21 ) for 15 min at room temperature in the dark. The reaction was visualised by a laser scanning confocal microscope. TUNELpositive cells exhibited green fluorescence.
Statistical analysis
Quantitative data were expressed as mean6SE. Statistical analysis was performed with SPSS version 13.0 (SPSS Inc., Chicago, IL, USA), and one-way ANOVA was used to compare the differences between groups. P,0.05 was considered statistically significant.
RESULTS

Antitumour activity of si-Stat3
To evaluate the effects of HAP-mediated si-Stat3 transfection on the growth of prostate cancer in vivo, the antitumour efficacy was determined using a prostate cancer RM-1 mouse model. Primary tumour blocks (1.5 mm 3 ) were implanted into the right abdomens of C57BL/6 mice as previously described. 16 On day 5, tumours were visible at the sites of implantation (mean volume: 52.7612.1 mm 3 , n58). Cancer bearing mice were independently injected intratumourally with PBS, HAP-si-scramble or HAP-si-Stat3, which was repeated on day 20. The animals were killed on day 32, and the tumour sizes were measured (Table 1) . A significant difference in tumour size was found between the mice treated with PBS alone and those treated with si-scramble (P,0.05). Moreover, the mice treated with si-Stat3 showed markedly Plasmid (Figure 1 ; P,0.01).
Stat3 expression
To determine the ability of these plasmids to silence Stat3 expression, RT-PCR and Western blot assay were used to analyse Stat3 expression in tumours. The results indicated that the mRNA expression of Stat3 and the protein expression of Stat3 and p-Stat3 were markedly reduced in tumours treated with si-Stat3 compared with tumours treated with si-scramble or PBS alone (P,0.01; Figure 2 ).
The antitumour effects of si-Stat3
To determine the mechanism underlying the in vivo antitumour effects of si-Stat3, tumours were obtained and processed for immunohistochemistry and TUNEL assay. Immunohistochemical examination showed that the levels of Stat3, PCNA and CD34 were remarkably reduced by si-Stat3 treatment when compared to the levels in the control group (Figure 3a-c) . The proliferation index was 15.662.8% in the siRNA-Stat3 group, which was significantly lower than in the control group (P,0.01, Table 2 ). The TUNEL assay showed that si-Stat3-treated cancers underwent massive apoptosis characterised by sparsely dispersed chromatin and necrotic tissues, as shown in Figure 3d and Table 2 . The apoptosis index was 42.566.4% in the si-Stat3 group, which was markedly higher than that in the control group (P,0.01). Hematoxylin and eosin staining showed that si-Stat3-treated tumours underwent high levels of apoptosis. There was no apparent invasion of the tumour into other tissues (data not shown). Si-Stat3 treatment suppressed the expression of CD34 in tumours, thereby suppressing cancer growth. These findings suggest that CaCl 2 -modified HAP can be used for the delivery of siStat3 into tumours, exerting potent antitumour effects.
Expressions of Stat3-associated genes
Recent studies have indicated that constitutively active Stat3 can induce the expression of several genes, including Bcl-2 (which encodes an anti-apoptotic protein) and cyclin D1 (which promotes cell , and on day 5, these mice were divided into three groups and injected intratumourally with PBS, si-Stat3 or si-scramble. This injection was repeated on day 20, and the tumour sizes were determined every 2 days. Data are presented as means6s.e. (n58). *P,0.01 versus mock and si-scramble. PBS, phosphate-buffered saline; siRNA, small interfering RNA. . 17 To determine the effects of si-Stat3 treatment on the expression of Stat3-associated genes, Western blot assays were performed. The results showed that the levels of Bcl-2, VEGF and cyclin D1 proteins were dramatically downregulated in tumours, but Bax and Caspase3 levels were markedly elevated after si-Stat3 treatment when compared with controls ( Figure 4) . These results imply that siStat3 treatment interfered with the transcriptional activity of Stat3, subsequently reducing the expression of its downstream genes.
DISCUSSION
Prostate cancer is a common disease in the elderly. In 2009, the new cases and deaths from prostate cancer in the United States were estimated to be 192 280 and 27 360, respectively. 18 In China, the incidence of prostate cancer has increased over time. 19 Surgery and radiotherapy with or without androgen deprivation therapy) are the most effective therapeutic strategies for prostate cancer. However, there is currently no effective treatment for patients with advanced prostate cancer at diagnosis and those who do not respond to primary curative attempts. It is imperative to develop novel, more effective strategies to treat prostate cancer. Because prostate cancer represents an accumulation of genetic mutations in cells that have gone awry, a novel approach against this cancer is gene therapy. 20 Signal transducers and activators of transcription (STAT) proteins are a family of seven proteins (Stats 1, 2, 3, 4, 5a, 5b and 6) that mediate the transduction of extracellular signals to the transcription of target genes. Among the STATs, Stat3 is the most important, being closely linked to tumourigenesis. 21, 22 Stat3 is a transcription factor and has been found in an activated state in numerous primary tumours. 23, 24 Constitutive Stat3 signalling represents one of the key molecular events in the multistep process leading to carcinogenesis. For these reasons, the Stat3 signalling pathway can be used as a potential target in antitumour therapy. 25 In our previous study, DNA vector-based Stat3-specific RNAi was used to block Stat3 signalling. 12 However, the efficacy of siRNAmediated interference depends on the efficient delivery of siRNA oligonucleotides. The challenge for siRNA delivery is even greater when the aim is to inhibit the in vivo expression of target genes. Delivering siRNA to animal tissues in vivo is a complicated process and involves Plasmid-based Stat3 siRNA ZW Liang et al 484 physical, chemical or biological approaches or a combination of them in some cases. 26 The major weaknesses limiting the wide application of most delivery systems are the potential for mutagenesis or oncogenesis, host immune responses and high cost. 27 Non-viral siRNA delivery to tissues does not elicit an immune response, has a great advantage in drug target validation and allows multiple administrations of siRNA, attributes that are crucial for the therapeutic application of siRNA. Sun et al.
11 successfully used HAP nanoparticles as a novel vector for inner ear gene therapy. Our results showed that CaCl 2 -modified HAP can mediate the transfection of si-Stat3 plasmids into mouse prostate cancer in vivo, resulting in the significant inhibition of cancer growth. Our results were consistent with reports that the transfection efficiency of HAP nanoparticles can reach as high as approximately 50-80% of that of liposome-mediated transfection. 10 In addition, our study showed that HAP alone could also exert antitumour effects: HAP carrying si-scramble could inhibit cancer growth compared to the control; this was consistent with the study of Zhu et al., in which HAP alone could inhibit the in vitro proliferation of hepatocellular carcinoma cells. 10 Thus, the antitumour effects of HAP nanoparticles may be further enhanced when combined with Stat3-specific siRNA.
Our results showed that the levels of Stat3 mRNA and protein were downregulated in cancer tissues after si-Stat3 treatment, indicating that HAP can deliver Stat3-specific siRNA into cancer cells, resulting in the inhibition of Stat3 expression. PCNA is a nuclear proliferation antigen, and its activation is closely related to cell proliferation. 28 Our immunohistochemical examination showed that PCNA-positive cells were decreased in the si-Stat3 treatment group compared to controls, indicating that the downregulated expression of PCNA may be due to the suppression of Stat3 expression by si-Stat3 and may lead to inhibited proliferation of cancer cells. The TUNEL assay showed that apoptosis in the si-Stat3 group was significantly increased. These findings reveal that the HAP carrying the si-Stat3 can exert a potent antitumour effect in vivo by suppressing proliferation and promoting apoptosis of cancer cells. Furthermore, our results showed that the expression of pro-apoptotic factors including Bax and Caspase3 was markedly upregulated in the si-Stat3 group. However, anti-apoptotic factors such as Bcl-2 and cyclin D1 were reduced significantly. Studies have demonstrated that Stat3 can upregulate the expression of several anti-apoptotic proteins, including Bcl-2 and Bcl-xL, 29 which are key components of mitochondrial apoptotic pathways. Therefore, si-Stat3 transfection-induced apoptosis of cancer cells may be caused in part by the activation of mitochondrial apoptosis pathways. 30 Additionally, immunostaining assays revealed massive CD34 expression in cancers, an indicator of microvessel density in tissues. However, the expression of CD34 in tumours was significantly decreased after si-Stat3 transfection, which was concurrent with the downregulation of VEGF, another gene downstream of Stat3, demonstrated by western blot assay. The reduced VEGF level resulting from Stat3 knockdown was expected because VEGF expression has been shown to be upregulated by Stat3. 31 The downregulation of angiogenesis related factors (CD34 and VEGF) may lead to the suppression of cancer growth, resulting in reduced tumour size.
In conclusion, we have confirmed for the first time that HAP nanoparticles can be used as vectors in the in vivo delivery of plasmid-based siRNAs into cancers. The HAP nanoparticles carrying si-Stat3 exhibited tumour-suppressive effects. These findings revealed that HAP may be used as an effective gene delivery tool. However, further modification of HAP is needed for high transfection efficiency and convenient clinical applications. Ultimately, we predict that research into in vivo siRNA delivery will translate into many clinically viable administration methods for siRNA-based therapeutics to treat various cancers.
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